Maxim Pharmaceutical Phase 3 Trial for Advanced Malignant Melanoma Fails to Meet Primary Endpoint
September 20, 2004 02:07 ET
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden and SAN DIEGO, Sept. 20, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced that its confirmatory Phase 3 trial (M104) of the investigational drug...
Maxim Pharmaceuticals Announces 2004 Third Quarter Financial Results
August 03, 2004 02:02 ET
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden and SAN DIEGO, Aug. 3, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals, Inc. (Nasdaq:MAXM) (SSE:MAXM) today announced results for the quarter ended June 30, 2004, the third quarter of its...
Maxim Pharmaceuticals Announces Appointment of Richard A. Mafrica as Vice President Commercialization
July 27, 2004 01:53 ET
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden and SAN DIEGO, July 27, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced the appointment of Richard A. Mafrica, 47, to the newly created position...
Maxim Pharmaceuticals Added to Russell 2000 Index
June 29, 2004 02:09 ET
|
Maxim Pharmaceuticals
SAN DIEGO, June 29, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced that its stock has been added to the Russell 2000 Index.
The annual reconstitution of Russell's 21...
Maxim Pharmaceuticals Added to Nasdaq Biotechnology Index
May 25, 2004 03:07 ET
|
Maxim Pharmaceuticals
SAN DIEGO, May 25, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced that it has been added to the NASDAQ Biotechnology Index(r) (NBI). All securities in the Index...
Maxim Pharmaceuticals Announces Final Dismissal Of Federal Lawsuit
May 20, 2004 08:36 ET
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden, May 20, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals, Inc. (Nasdaq:MAXM) (SSE:MAXM) announced that the Plaintiff in the Company's federal class action securities complaint has dropped...
Maxim Pharmaceuticals Presents New Preclinical Results Showing Prevention Of Liver Injury By Histamine
May 18, 2004 03:12 ET
|
Maxim Pharmaceuticals
SAN DIEGO and STOCKHOLM, Sweden, May 18, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced preclinical results demonstrating the ability of histamine to prevent...
Maxim Pharmaceuticals Announces Phase 3 Trial of Ceplene in Acute Myeloid Leukemia Meets Primary Trial Endpoint
May 12, 2004 03:06 ET
|
Maxim Pharmaceuticals
San Diego, Calif. and STOCKHOLM, Sweden, May 12, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced the results of an international Phase 3 clinical trial testing the...
Maxim Pharmaceuticals Announces 2004 Second Quarter Financial Results
May 04, 2004 03:21 ET
|
Maxim Pharmaceuticals
SAN DIEGO, Calif., and STOCKHOLM, Sweden, May 4, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals, Inc. (Nasdaq:MAXM) (SSE:MAXM) today announced results for the quarter ended March 31, 2004, the second...
Maxim Pharmaceuticals Presents Preclinical Data on Histamine's Ability to Prevent Liver Damage
April 19, 2004 03:23 ET
|
Maxim Pharmaceuticals
SAN DIEGO, April 19, 2004 - Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced preclinical results indicating that histamine may prevent lipopolysaccharide (LPS)-induced liver injury. The...